http://www.summitplc.com/
Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the superbug C. difficile

dreamcatcher, I guess this is one of yours - pity today's fall from grace - but these things happen in Biotech. Today, sp 48p on News of Trial halting.... that's a massive 78% fall from grace...but I wonder that it ever was worth the higher figure; since the number of patients is relatively small and not all can afford £ots of money to pay-back the Research Costs.
What now, I wonder . . . what's their Cash position and are there any Liabilities, such as Loans outstanding...?
EDIT(12Dec2018)-sp 19p after a serious fall (again). but PE ratio -1.2 DYOR.

No, not held this year.

Another of Jim Mellons favourites, Regent Pacific, which took over Plethora Solutions, and now listed in Hong Kong (ticker 575) is rolling out it's premature ejaculation spray Fortacin right across Europe this year through distributor Recordati.
There has been little PR about this...but according to Recordati they are very excited about Fortacins sales prospects.
And don't forget, Fortacin comes from the stable of Prof. Mike Whiley, and has full EU approval.
A good time to reinvest for some likely big gains.............maybe a better bet than Summit............

P.s. To previous posts, Regent Pacific can be held in an ISA, SIPP, or general trading account.......try iii.